三是提升学校命题能力。市、区（市）县两级教研部门将进一步强化命题能力培训，引导学校和教师树立正确的教育评价观，准确把握考试评价的诊断、改 进功能。同时对命题能力不足的学校，可由上级教育部门组织命题，提供题库供学校选用。 2、阿坝松潘县一砂场未封闭施工引发扬尘污染，能整改吗？ 问政四川网友提问：松潘岷江实业有限责任公司毛儿盖砂场未封闭施工。所有设备生产线全部暴露在露天环境下，对环境造成了扬尘和噪音污染。希望相关 部门督促该企业立即整改，尽快完成厂房封闭，杜绝环境污染。 1、成都家长呼吁，能否恢复高一高二全市统一调研考试？ 问政四川网友提问：我是一名成都高一学生的家长，得知取消高一高二全市统一调研考试，有点担心。高中阶段核心任务是为学生升入高等学校或步入社会 做准备，兼具基础性与选拔性。高一高二若完全取消区域性调研考试，仅依靠各校自主命题考试，存在以下问题：各校命题难度、范围、评分标准差异大， 无法客观衡量学生在本区域的真实水平，更难以对标高考要求，高考备战如"开盲盒"；相对偏远学校的学生可能因缺乏区域参照，难以发现自身差距，加剧 教育资源不均衡带来的隐性差距。希望教育部门重新评估高中非毕业年级统考的必要性，在规 ...

Summary of Glaukos Conference Call Company Overview - **Company**: Glaukos Corporation - **Products Discussed**: Epioxa and iDose - **Industry**: MedTech, specifically focused on ophthalmic therapies Key Points Epioxa Pricing and Market Dynamics - Epioxa pricing was established after extensive research and consideration of value for patients, providers, and the payer system [5][6] - The company aims to maximize patient awareness and provider education, which is costly but essential for accessing therapies [7][8] - There are approximately 5 million cataract procedures annually in the U.S., but only about 10,000 patients are currently treated with FOTREXA, indicating a significant opportunity for Epioxa [6][9] - The gross-to-net dynamics for Epioxa include: - A 23% statutory discount for Medicaid patients [11] - A similar discount for sales to 340B public hospital systems [11] - Coverage of out-of-pocket costs for commercial patients to ensure access [12][13] Physician Reactions and Market Access - Initial physician feedback on Epioxa pricing has been mixed, with some expressing shock and unrest [15] - The company emphasizes that pricing decisions were made with patient access as a priority, and they are prepared to engage with physicians to explain their rationale [15][16] - The reimbursement landscape for Epioxa is expected to be non-linear, differing from the iDose experience due to the patient demographics and the number of insurance plans involved [19][20] Patient Volume and Market Potential - The U.S. market for Epioxa is estimated to have around 10,000 patients, with potential to reach 20,000 eyes at peak [23] - The company believes there are significantly more undiagnosed patients with keratoconus, indicating a larger market opportunity [25][26] - The goal is to not only return to previous treatment levels but to expand significantly beyond that [25][26] Comparison with iDose - The peak sales opportunity for iDose is viewed as larger than Epioxa due to a larger patient population (21 million potential ocular hypertensive and glaucomatous eyes) [27][28] - iDose is expected to benefit from a more established market and clearer treatment guidelines compared to Epioxa, which is in a rare disease category [21][22] Reimbursement and Market Access Challenges - The company is confident in the long-term access for iDose despite potential hurdles from the CAC (Coverage Advisory Committee) discussions [29][30] - The reimbursement process is complex, with a need for extensive data to support market access [30][31] - The company is optimistic about the potential for Medicare Advantage plans to cover iDose, which could expand access significantly [34][36] Future Outlook - The company is focused on driving incremental utilization in both commercial and Medicare Advantage populations [56][57] - There is a belief that the dynamics of patient access will improve over time as the company continues to engage with payers and physicians [35][36] Additional Insights - The company acknowledges the challenges of competing for operating room time during peak cataract surgery seasons, which may impact iDose sales [44][45] - The management is cautious about setting revenue expectations, considering various scenarios for both Epioxa and iDose [50][52] This summary encapsulates the key discussions and insights from the Glaukos conference call, highlighting the company's strategic focus on pricing, market access, and future growth opportunities in the ophthalmic therapy space.